Henry C. Maguire
University of Pennsylvania
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Henry C. Maguire.
The Journal of Infectious Diseases | 2001
Joo-Sung Yang; J. Joseph Kim; Daniel Hwang; Andrew Y. Choo; Kesen Dang; Henry C. Maguire; Sagar Kudchodkar; Mathura P. Ramanathan; David B. Weiner
West Nile virus (WNV) is a vectorborne pathogen that induces brain inflammation and death. Recently, confirmed cases of infection and deaths have occurred in the United States Mid-Atlantic region. In this study, a DNA vaccine encoding the WNV capsid protein was constructed, and the in vivo immune responses generated were investigated in DNA vaccine-immunized mice. Antigen-specific humoral and cellular immune responses were observed, including a potent induction of antigen-specific Th1 and cytotoxic T lymphocyte responses. Strong induction of Th1-type immune responses included high levels of antigen-specific elaboration of the Th1-type cytokines interferon-gamma and interleukin-2 and beta-chemokines RANTES (regulated upon activation, normal T cell-expressed and secreted) and macrophage inflammatory protein-1beta. Dramatic infiltration of CD4 and CD8 T cells and macrophages also was observed at the muscle injection site. These results support the potential utility of this method as a tool for developing immunization strategies for WNV and other emerging pathogens.
Journal of Medical Primatology | 1999
Jong J. Kim; Liesl K. Nottingham; Anthony Tsai; Daniel J. Lee; Henry C. Maguire; Jim Oh; Tzvete Dentchev; Kelledy Manson; Michael S. Wyand; Michael G. Agadjanyan; Kenneth E. Ugen; David B. Weiner
Abstract: DNA or nucleic acid immunization has been shown to induce both antigen‐specific cellular and humoral immune responses in vivo. Moreover, immune responses induced by DNA immunization can be enhanced and modulated by the use of molecular adjuvants. To engineer the immune response in vivo towards more T‐helper (Th)1‐type cellular responses, we investigated the co‐delivery of inteferon (IFN)‐γ, interleukin (IL)‐12, and IL‐18 genes along with DNA vaccine constructs. We observed that both antigen‐specific humoral and cellular immune responses can be modulated through the use of cytokine adjuvants in mice. Most of this work has been performed in rodent models. There has been little confirmation of this technology in primates. We also evaluated the immunomodulatory effects of this approach in rhesus macaques, since non‐human primates represent the most relevant animal models for human immunodeficiency virus (HIV) vaccine studies. As in the murine studies, we also observed that each Th1 cytokine adjuvant distinctively regulated the level of immune responses generated. Co‐immunization of IFN‐γ and IL‐18 in macaques enhanced the level of antigen‐specific antibody responses. Similarly, co‐delivery of IL‐12 and IL‐18 also enhanced the level of antigen‐specific Th proliferative responses. These results extend this adjuvant strategy in a more relevant primate model and support the potential utility of these molecular adjuvants in DNA vaccine regimens.
Pathobiology | 1991
Thomas M. Williams; David B. Weiner; Mark I. Greene; Henry C. Maguire
The c-erbB-2 (neu) gene encodes a transmembrane phosphoglycoprotein (p185erbB-2) which resembles a growth factor receptor-like molecule closely related to the epidermal growth factor receptor. Overexpression of c-erbB-2 induces cell transformation in vitro. Poorer survival rates and elevated recurrence rates following treatment have been shown in patients whose breast adenocarcinomas demonstrate increased c-erbB-2 expression. Using immunoprecipitation and immunoperoxidase staining, we surveyed human cell lines for p185erbB-2. Cell lines from most tumor types (e.g. lymphomas, neuroblastomas, melanomas) demonstrated negligible p185erB-2; however, 3 of 6 pancreatic cell lines overexpressed c-erbB-2. Southern blot analysis revealed that c-erbB-2 was amplified in two of these cell lines and was both rearranged and amplified in one of them. Based on these findings, we examined tissue sections from archival specimens of primary human pancreatic adenocarcinomas. A substantial proportion of specimens had increased p185erbB-2, as judged by increased immunostaining of the tumor cells. In such pancreatic tumors p185erbB-2 may contribute to the malignant phenotype and could provide a target for immunodiagnostic or immunotherapeutic strategies.
Oncogene | 2002
Karuppiah Muthumani; Donghui Zhang; Daniel S. Hwang; Sagar Kudchodkar; Nathanael S. Dayes; Brijal M. Desai; Afshan S. Malik; Yang Js; Michael A. Chattergoon; Henry C. Maguire; David B. Weiner
The targeted delivery of genes whose products arrest the cell cycle and/or induce apoptosis represent an important tool for the understanding and controlling forms of unregulated cell growth. The vpr gene product of HIV-1 has been reported to interfere with cell growth and induce apoptosis, but the mechanism of its action is not clearly understood. In order to study these important properties of Vpr, we created a recombinant adenovirus H5.010CMV-vpr (adCMV-vpr) as a tool to deliver the vpr gene to various cell lines to examine its biology. Vpr protein expression was confirmed by Western blot analysis in adCMV-vpr infected cells. We tested the effects of adCMV-vpr on cell growth of several tumor cell lines. Infection of both p53 positive and p53 deficient tumor cell lines with adCMV-vpr resulted in dramatic induction of cell death in short-term assays. We observed that apoptosis was induced through the mitochondrial pathway as we observed changes in the cytochrome c content accompanied by caspase 9 activation. As Bcl-2 is reported to interfere with apoptosis through the mitochondrial pathway, we examined the effect of adCMV-vpr in Bcl-2 over expressing cell lines. We observed that Bcl-2 overexpression does not inhibit adCMV-vpr induced apoptosis. The properties of adCMV-vpr inducing apoptosis through caspase 9 in a p53 pathway independent manner suggest that this is an important reagent. Such a vector may give insight into approaches designed to limit the growth of pathogenic human cells.
Gene Therapy | 2010
Michele Kutzler; Kimberly A. Kraynyak; S J Nagle; Rose Parkinson; D Zharikova; Michael A. Chattergoon; Henry C. Maguire; Karuppiah Muthumani; Kenneth E. Ugen; David B. Weiner
A hurdle facing DNA vaccine development is the ability to generate strong immune responses systemically and at local immune sites. We report a novel systemically administered DNA vaccination strategy using intramuscular codelivery of CCL27 or CCL28, which elicited elevated peripheral IFN-γ and antigen-specific IgG while driving antigen-specific T-cell secretion of cytokine and antibody production in the gut-associated lymphoid tissue and lung. This strategy resulted in induction of long-lived antibody responses that neutralized influenza A/PR8/34 and protected mice from morbidity and mortality associated with a lethal intranasal viral challenge. This is the first example of the use of CCL27 and CCL28 chemokines as adjuvants to influence a DNA vaccine strategy, suggesting further examination of this approach for manipulation of vaccine-induced immunity impacting both quality and phenotype of responses.
Journal of Allergy | 1961
Henry C. Maguire; Howard I. Maibach
Abstract An intraperitoneal injection of egg albumin along with the single course of a nitrogen mustard (cyclophosphoramide) was given to guinea pigs. Following a rest period of 3 months, a routine anaphylactic sensitization and challenge program resulted in 73 per cent survival in the experimental (pretreated) group and 9 per cent survival in the control group.
Pathobiology | 1992
Henry C. Maguire; Maria Hellman; Mark I. Greene; I. Yeh
Several lines of evidence have demonstrated that expression of the c-erbB-2 gene product contributes to the malignant phenotype. We and others have determined that c-erbB-2 is substantially expressed in most ductal in situ carcinomas of the comedo type, but not in other patterns of ductal carcinoma in situ or in atypical ductal hyperplasia of the breast. In the present investigation, by immunohistochemistry we inquired whether invasive ductal adenocarcinomas retained the c-erbB-2 expression status of the in situ carcinomas from which they derived. Of twelve specimens containing both cribriform/micropapillary in situ and derivative invasive adenocarcinomas in the same section, all tumor cells were negative for c-erbB-2 expression. In thirteen in situ carcinomas of the comedo type, with identifiable invasive components, ten had definite c-erbB-2 expression, and in every case there was comparable c-erbB-2 protein staining of in situ and invasive components; in three of these ten cases the staining in the in situ component tended to be more intense. These findings imply that a significant proportion of invasive mammary adenocarcinomas expressing c-erbB-2 protein is derived from ductal in situ carcinomas of the comedo type.
Pathobiology | 1990
Henry C. Maguire; Mark I. Greene
The c-erbB-2 oncogene encodes a transmembrane phosphoglycoprotein. This molecule appears to be a growth factor receptor in the family of tyrosine kinase growth factor receptors; however, its ligand has not yet been identified. Amplification and/or overexpression of c-erbB-2 in breast adenocarcinomas occurs frequently and its occurrence implies a more advanced malignancy. This functional tumor marker is readily identified by appropriate DNA and antibody probes. The large external domain of the c-erbB-2 gene product is a promising target for immunodiagnostic and immunotherapeutic modalities.
Archives of Dermatology | 1980
Henry C. Maguire
Dr Samman has presented us with a third edition of his now classic manual on nails. His is a brief, practical book. He introduces us to the subject with a chapter on the normal anatomy and physiology of nails. The following chapter, which is devoted to nail symptoms, describes the limited reaction patterns of nails. In the heart of the book, there is a succession of brief chapters dealing with the common nail diseases and with disorders, such as psoriasis, that typically produce changes in the nails. Dr Sammans prose is clear and eminently readable, and his presentation is never tentative or ambiguous. He bases his conclusions primarily on his own experience. His approach is in no wise encyclopedic. At the end of each chapter, there are a few key references, but a detailed examination of the literature dealing with nails is not attempted. This is a fine volume. It
Oncogene | 1989
Jeffrey A. Cohen; David B. Weiner; More Kf; Yasuo Kokai; Williams Wv; Henry C. Maguire; Virginia A. LiVolsi; Mark I. Greene